Sigyn Therapeutics, Inc. (OTCQB: SIGY) released a shareholder update authored by CEO Jim Joyce detailing the company's strategic initiatives, including a potential merger with a Nasdaq-listed company at risk of delisting and the sale of certain assets. The update addresses the company's inability to complete an uplist to Nasdaq financing and its impact on capital-raising efforts.
Joyce, who previously founded Aethlon Medical and led the development of the Hemopurifier—a device that received multiple FDA Breakthrough Device designations—highlighted Sigyn's CardioDialysis therapy. Designed for use on dialysis machines, CardioDialysis targets cholesterol-transporting lipoproteins and inflammatory molecules to treat cardiovascular disease, the leading cause of death worldwide. The therapy also shows potential for sepsis and traumatic brain injury (TBI). Joyce noted that lipoprotein apheresis devices, which reduce heart attacks and strokes more effectively than drugs, are limited to fewer than 60 specialized centers in the U.S., whereas CardioDialysis could be deployed at over 7,500 dialysis clinics.
The CEO explained that Sigyn went public through a merger with an OTC company, aiming to replicate his previous success with Aethlon Medical, which uplisted to Nasdaq. However, a planned firm commitment offering led by a FINRA member broker-dealer failed due to a regulatory catch-22: Nasdaq required review of investors before an effective SEC registration statement, while the SEC needed Nasdaq's contingent listing approval. After withdrawing the registration statement, Sigyn faced challenges in raising capital without diluting shareholder value.
Joyce referenced his January 15 shareholder update, which outlined strategies including asset sales and a potential merger with a Nasdaq-listed company at risk of not meeting the $5 million minimum market value of listed securities (MVLS) requirement. He encouraged shareholders to review that update for further details. As of March 11, 2026, the company had 2,330,042 shares outstanding.
Sigyn's pipeline also includes ImmunePrep to optimize immunotherapeutic antibody delivery, ChemoPrep to enhance chemotherapy targeting, and ChemoPure to reduce chemotherapy toxicity. The company's ability to advance these therapies depends on securing capital through strategic transactions.
